A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors

Cancer Discovery

Volumn 3, Issue 12, 2013, Pages 1364-1377

  Jahchan, Nadine S ^a   Dudley, Joel T ^a   Mazur, Pawel K ^a   Flores, Natasha ^a   Yang, Dian ^a   Palmerton, Alec ^a   Zmoos, Anne Flore ^a   Vaka, Dedeepya ^a   Tran, Kim Q T ^a   Zhou, Margaret ^a   Krasinska, Karolina ^a   Riess, Jonathan W ^b   Neal, Joel W ^a   Khatri, Purvesh ^a   Park, Kwon S ^a   Butte, Atul J ^a   Sage, Julien ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 PYRIDYL) ETHYLAMINE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACETYLCHOLINE; ADRENALIN; ANTHRA [1, 9 CD] PYRAZOL 6 (2H) ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AZELASTINE; BEPRIDIL; CISPLATIN; CLOMIPRAMINE; DOXAZOSIN MESYLATE; DOXORUBICIN; ETOPOSIDE; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR; IMIPRAMINE; ISOBUTYLMETHYLXANTHINE; MITOGEN ACTIVATED PROTEIN KINASE; PARGYLINE; PLATINUM; PROMETHAZINE; PROTEIN C JUN; PROTEIN P130; RITANSERIN; SEROTONIN; SEROTONIN 2 AGONIST; STRESS ACTIVATED PROTEIN KINASE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CALCIUM SIGNALING; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG REPOSITIONING; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MASS SPECTROMETRY; MOUSE; NECROSIS; NEUROENDOCRINE TUMOR; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DRUG REPOSITIONING; HUMANS; LUNG NEOPLASMS; MICE; NEUROENDOCRINE TUMORS; RECEPTORS, G-PROTEIN-COUPLED; SMALL CELL LUNG CARCINOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890027846     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0183     Document Type: Article

References (47)

1. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3: 673-83.
2. Li YY, An J, Jones SJ. A computational approach to finding novel targets for existing drugs. PLoS Comput Biol 2011; 7: e1002139.
3. Yang L, Agarwal P. Systematic drug repositioning based on clinical side-effects. PLoS ONE 2011; 6: e28025.
4. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011; 3: 96ra76.
5. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77.
6. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 2012; 8: e1002503.
7. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011; 378: 1741-55.
8. Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell 2012; 21: 448 e2.
9. Neal JW, Gubens MA, Wakelee HA. Current management of small cell lung cancer. Clin Chest Med 2011; 32: 853-63.
10. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2: 798-811.
11. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28: 3-13.
12. Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 2003; 9: 495-509.
13. Onganer PU, Seckl MJ, Djamgoz MB. Neuronal characteristics of small-cell lung cancer. Br J Cancer 2005; 93: 1197-201.
14. Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011; 17: 1504-8.
15. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart D L, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010; 70: 3877-83.
16. Kiselyov K, Shin DM, Muallem S. Signalling specificity in GPCRdependent Ca 222signalling. Cell Signal 2003; 15: 243-53.
17. Thompson MD, Burnham WM, Cole DE. The G protein-coupled receptors: pharmacogenetics and disease. Crit Rev Clin Lab Sci 2005; 42: 311-92.
18. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1: 11-21.
19. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230-40.
20. Fisar Z, Krulik R, Fuksova K, Sikora J. Imipramine distribution among red blood cells, plasma and brain tissue. Gen Physiol Biophys 1996; 15: 51-64.
21. Petersen RC, Richelson E. Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells. Psychopharmacology 1982; 76: 26-8.
22. Chen G, Hasanat KA, Bebchuk JM, Moore GJ, Glitz D, Manji H K. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med 1999; 61: 599-617.
23. Assanasen P, Naclerio RM. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin Allergy Immunol 2002; 17: 101-39.
24. Donati RJ, Rasenick MM. G protein signaling and the molecular basis of antidepressant action. Life Sci 2003; 73: 1-17.
25. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15: 1563-86.
26. Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011; 147: 1011-23.
27. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98: 13790-5.
28. Rohrbeck A, Neukirchen J, Rosskopf M, Pardillos GG, Geddert H, Schwalen A, et al. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med 2008; 6: 69.
29. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, et al. Molecular target class is predictive of in vitro response profile. Cancer Res 2010; 70: 3677-86.
30. Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 2001; 20: 1563-9.
31. Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 2007; 67: 3936-44.
32. Zhang S, Togo S, Minakata K, Gu T, Ohashi R, Tajima K, et al. Distinct roles of cholinergic receptors in small cell lung cancer cells. Anticancer Res 2010; 30: 97-106.
33. Rasenick MM, Chaney KA, Chen J. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. J Clin Psychiatry 1996; 57 (Suppl 13): 49-55.
34. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990; 42: 45-83.
35. Billington CK, Penn RB. m3 muscarinic acetylcholine receptor regulation in the airway. Am J Respir Cell Mol Biol 2002; 26: 269-72.
36. Chen ZJ, Minneman KP. Recent progress in alpha1-adrenergic receptor research. Acta Pharmacol Sin 2005; 26: 1281-7.
37. Traish AM, Moreland RB, Gallant C, Huang YH, Goldstein I. G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells. Recept Signal Transduct 1997; 7: 121-32.
38. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002; 35: 605-23.
39. Shinoura H, Shibata K, Hirasawa A, Tanoue A, Hashimoto K, Tsujimoto G. Key amino acids for differential coupling of alpha1-adrenergic receptor subtypes to Gs. Biochem Biophys Res Commun 2002; 299: 142-7.
40. Moniri NH, Booth RG. Role of PKA and PKC in histamine H1 receptor-mediated activation of catecholamine neurotransmitter synthesis. Neurosci Lett 2006; 407: 249-53.
41. Schroder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 2010; 28: 943-9.
42. Gerits N, Kostenko S, Shiryaev A, Johannessen M, Moens U. Relations between the mitogen-activated protein kinase and the cAMPdependent protein kinase pathways: comradeship and hostility. Cell Signal 2008; 20: 1592-607.
43. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315: 115-22.
44. Walker AJ, Card T, Bates TE, Muir K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer 2011; 104: 193-7.
45. McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 2011; 20: 260-75.
46. Li L, Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 2013; 153: 86-100.
47. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012; 149: 780-94.